Yusuke Okuma

Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Trends in GPCR drug discovery: new agents, targets and indications

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond

Paclitaxel: What has been done and the challenges remain ahead

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

Gut microbiota and Covid-19- possible link and implications

Tumour burden and efficacy of immune-checkpoint inhibitors

Microbiota Modulation of the Gut-Lung Axis in COVID-19

Immune checkpoint inhibitors: recent progress and potential biomarkers

G Protein-Coupled Receptor Signaling in Stem Cells and Cancer

Exosomes

Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity

Revisiting the PD-1 pathway

Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application

Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy

A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer

Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer

Impact of prior antibiotic use on the efficacy of nivolumab for non‑small cell lung cancer

Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.